Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7449194 | 0.94 | SIGMAR1 (0.57) | SIGMAR1CHRNB2CHRNA4ALDH1A1CYP1A2 | |
| SCHEMBL737232 | 0.87 | — | — | |
| SCHEMBL221597 | 0.83 | SIGMAR1 (0.54) | SIGMAR1CHRNB2CHRNA4ALDH1A1CYP1A2 | |
| SCHEMBL7019855 | 0.78 | SIGMAR1 (0.57) | SIGMAR1CHRNB2CHRNA4ALDH1A1CYP1A2 | |
| SCHEMBL5604 | 0.71 | TSHR (0.48) | ALDH1A1 | |
| SCHEMBL29518090 | 0.70 | — | — | |
| SCHEMBL2388666 | 0.70 | — | — | |
| 5,6,7,8-Tetrahydroisoquinoline SCHEMBL28211 | 0.70 | SIGMAR1 (1.00) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| Bromide SCHEMBL11831501 | 0.70 | TSHR (0.46) | ALDH1A1 | |
| SCHEMBL736652 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069188-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2021-03-11 | — | — | US | claimed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | claimed |
| EP-3630770-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | Relay Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | claimed |
| WO-2018218133-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | claimed |
| JP-H08509967-A | — | — | 1996-10-22 | — | — | JP | claimed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | claimed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | claimed |
| US-12042513-B2 | Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024151519-A2 | PPARG MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) | 2024-07-18 | — | — | WO | disclosed |
| CN-118339152-A | Macrocyclic compounds having farnesyl transferase inhibitory activity | 库拉肿瘤学公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240226302-A1 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228671-A1 | POLYPEPTIDYL LINKERS | Quantum-Si Incorporated (US) | 2024-07-11 | — | — | US | disclosed |
| WO-1999025752-A1 | FUNCTIONALIZED RESIN FOR THE SYNTHESIS OF AMIDES AND PEPTIDES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999020275-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| US-5753659-A | ANTICOAGULANTS FOR BLOOD DISORDER, CARDIOVASCULAR DISORDER, THROMBOSIS, | ZENECA LIMITED (GB) | 1998-05-19 | — | — | US | disclosed |
| US-5750754-A | TERTIARY BUTYL 3-METHYL-4-SUBSTITUTED BUTYRATE; CHEMICAL INTERMEDIATES FOR ANTICAOGULANT DRUGS | ZENECA LIMITED (GB) | 1998-05-12 | — | — | US | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226302-A1 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | CPT1B, IGF2BP2, IGF2BP3 | SIGMAR1 1334/4885CHRNB2 2333/4885CHRNA4 2781/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | SIGMAR1 2801/4885CHRNB2 2058/4885CHRNA4 2465/4885 |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | SIGMAR1 3199/4885CHRNB2 3932/4885CHRNA4 4622/4885 |
| US-20240228671-A1 | POLYPEPTIDYL LINKERS | VIP, DNPEP, PREP | SIGMAR1 4729/4885CHRNB2 4440/4885CHRNA4 4768/4885 |
| US-20210069188-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN2, PTPN5, PTPRJ | SIGMAR1 3884/4885CHRNB2 3961/4885CHRNA4 4647/4885 |
| US-12042513-B2 | Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof | CRBN, PSMA6, PSMA3 | SIGMAR1 4158/4885CHRNB2 4325/4885CHRNA4 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.